Sign Up to like & get
recommendations!
2
Published in 2023 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004780
Abstract: Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to initial nivolumab…
read more here.
Keywords:
cell;
salvage nivolumab;
treatment;
histology ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5006
Abstract: 5006Background: Nivolumab (nivo) is FDA approved for pts with VEGFR TKI-resistant RCC and the nivo + ipilimumab (nivo/ipi) combination is FDA approved for treatment naive pts with IMDC intermediate...
read more here.
Keywords:
nivolumab salvage;
treatment;
rcc;
salvage nivolumab ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.305
Abstract: 305Background: Although not officially approved, salvage nivolumab plus ipilimumab (nivo/ipi) treatment after prior PD-1/PD-L1 immune checkpoint inhibition is frequently used in metastatic renal ce...
read more here.
Keywords:
treatment;
plus ipilimumab;
salvage nivolumab;
metastatic renal ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2022 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.21.02938
Abstract: PURPOSE To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker of nivolumab monotherapy efficacy in treatment-naive patients with clear cell renal cell carcinoma (ccRCC) and the efficacy of…
read more here.
Keywords:
cell;
salvage nivolumab;
risk;
treatment ... See more keywords